Shionogi & Co., Ltd. (SGIOY) Stock Price & Analysis
Shionogi & Co., Ltd. (SGIOY) — price $9.81 (-0.61%), as of the Nov 18, 2026 trading session; market cap $16.7B.
Educational signal · not a buy or sell recommendation · How to read this
Shionogi & Co., Ltd. · SGIOY · Healthcare · Drug Manufacturers - Specialty & Generic
Shionogi & Co., Ltd. operates as a Japanese pharmaceutical enterprise, dedicated to the discovery, creation, manufacturing, and commercialization of a diverse array of medicines, diagnostic reagents, and medical equipment within Japan.
Price as of Nov 18, 2026
Key Statistics
No MoonshotScore yet: we have not published a score for this company.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $9.81 | |
| Change on the day | -0.61% | |
| 52-week range | $8.15–$12.00 | |
| Market capitalisation | $16.7B | — |
| Price / earnings (trailing) | 11.26 | |
| Shares traded on the day | 4.3K | |
| Beta (volatility vs the S&P 500) | 0.03 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Shionogi & Co. (SGIOY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
5 lenses, 5 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Shionogi & Co. (SGIOY), and what does it report?
Short answer
Shionogi & Co., Ltd. operates as a Japanese pharmaceutical enterprise, dedicated to the discovery, creation, manufacturing, and commercialization of a diverse array of medicines, diagnostic reagents, and medical equipment within Japan. Healthcare / Drug Manufacturers Specialty & Generic SEC filing business address: 5-54 Ofukacho, Kita-KU, Grand Green Osaka, Park Tower 26F, Osaka, 530-0011. It employs 6,223 people and is led by Isao Teshirogi. The market values it at $16.7B.
What are the financial strengths and risks for Shionogi & Co. (SGIOY)?
Short answer · as of
The distress and quality screens read Altman Z 3.24 · Piotroski F 5. Trailing ratios: ROE 14.4% · ROA 9.1% · current ratio 1.24 · earnings yield 8.7% · free-cash-flow yield 8.9%.
What should you watch next at Shionogi & Co. (SGIOY)?
Short answer · as of
Analyst estimates on file carry FY2027 revenue $720.53B · EPS 136.00 · 5 analysts.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- Fewer than two score snapshots exist, so no score trend is shown.
Checked against the records this page reads, on the dates shown above.
How is Shionogi & Co. scored?
Research dated 2026-09-13.
Shionogi is classified with specialty and generic manufacturers, but its business is not a generic-volume proposition. It combines marketed infectious-disease medicines with diagnostic products, medical equipment and development programs spanning a wide range of therapeutic areas.
Compared with a narrower drugmaker, Shionogi carries a broader scientific agenda and a substantial recurring research burden. Consolidated gross profit, research spending and pipeline conversion therefore reveal more about its economics than the industry label alone.
SGIOY also offers an over-the-counter security tied to an Osaka-based Japanese operator. Its reported institutional footprint is sparse and the disclosed leading positions are limited, a distinction in the security’s ownership context rather than in the underlying medical portfolio.
| Company | Price | Market value | Score |
|---|---|---|---|
| $0.37 Nov 18, 2026 | $5.98B | — Model unavailable | |
| $51.05 Nov 18, 2026 | $17.8B | — Model unavailable | |
| $102.14 Nov 18, 2026 | $12.0B | — Model unavailable | |
| $1.12 Nov 18, 2026 | $12.8B | — Model unavailable | |
| $26.70 Nov 18, 2026 | $13.4B | — 5-pillar · not comparable | |
| $14.98 Nov 18, 2026 | $12.5B | — 5-pillar · not comparable | |
| $20.28 Nov 18, 2026 | $23.3B | — 5-pillar · not comparable | |
| $85.57 Nov 18, 2026 | $34.8B | — 5-pillar · not comparable | |
| $21.88 Nov 18, 2026 | $7.62B | — 5-pillar · not comparable | |
| $9.08 Nov 18, 2026 | $39.8B | — 5-pillar · not comparable | |
| $102.00 Nov 18, 2026 | $6.67B | — 5-pillar · not comparable | |
| $28.96 Nov 18, 2026 | $6.02B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $720.53B
- EPS estimate
- $136.00
Measured against a quoted price of $9.81 (as of Nov 18, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held SGIOY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported SGIOY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Shionogi & Co. (SGIOY) — Healthcare
These answers are editorial: 1 of these 8 answers is drawn from the SGIOY research dossier (written Mar 18, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is SGIOY a good stock to buy?
Stock Expert AI does not rate SGIOY buy, sell or hold. Shionogi & Co., Ltd. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the SGIOY stock price today?
The last price recorded for Shionogi & Co., Ltd. (SGIOY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What does Shionogi & Co., Ltd. do?
Shionogi & Co., Ltd. is a research-driven pharmaceutical company focused on developing and commercializing innovative medicines. The company's core business involves the discovery, development, manufacture, and marketing of pharmaceutical products, diagnostic reagents, and medical devices.
What are the key factors to evaluate for SGIOY?
Evaluate SGIOY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. This expansion could be achieved through partnerships or direct investment in overseas operations. Not financial advice.
How frequently does SGIOY data refresh on this page?
SGIOY's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven SGIOY's recent stock price performance?
Shionogi & Co., Ltd. (SGIOY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong pipeline of drugs in development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SGIOY overvalued or undervalued right now?
The trailing P/E of Shionogi & Co., Ltd. (SGIOY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SGIOY before investing?
Before investing in Shionogi & Co., Ltd. (SGIOY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 1 from SEC filings and earnings calls, 11 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com